Anzeige
Mehr »
Login
Donnerstag, 14.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Investment in die Zukunft: Absoluter Geheimtipp - diese Aktie beschleunigt deine Renditechancen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JCLB | ISIN: FR0011049824 | Ticker-Symbol: 4ZG
Frankfurt
14.11.24
08:10 Uhr
4,200 Euro
+0,215
+5,40 %
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
MEDIAN TECHNOLOGIES Chart 1 Jahr
5-Tage-Chart
MEDIAN TECHNOLOGIES 5-Tage-Chart
RealtimeGeldBriefZeit
4,1404,23517:55

Aktuelle News zur MEDIAN TECHNOLOGIES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiMedian Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of October 31st, 2024173Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares...
► Artikel lesen
07.11.Median Technologies Hosted Insightful Key Opinion Leader (KOL) Webinar on eyonis Lung Cancer Screening (LCS) REALITY Data180Two globally leading pulmonologists reviewed REALITY data, AI and the potential impact on lung cancer screening Replay in English is available on the link here A French subtitled...
► Artikel lesen
30.10.Median Technologies to Host Key Opinion Leader (KOL) Webinar on AI and Lung Cancer Screening205Webinar to focus on the eyonis Lung Cancer Screening (LCS) REALITY data November 7, 2024 1:30 pm CET 7:30 am ET Registration link Regulatory News: Median Technologies (FR0011049824, ALMDT...
► Artikel lesen
24.10.Median Technologies Reports 2024 Q3 Operational and Financial Update and 2024 Half-Year Results192eyonis LCS pivotal REALITY study met all primary and secondary endpoints A webcast including Key Opinion Leaders will be held on November 7, 2024, to discuss the REALITY study results ...
► Artikel lesen
07.10.Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of September 30th, 2024216Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares ...
► Artikel lesen
11.09.Median Technologies to Attend and Present at the ESMO Congress 2024, Being Held in Barcelona, Spain, from Sept 13-17, 2024400Peer-reviewed scientific poster for eyonis LCS Median iCRO eyonis teams will be at booth #525, Exhibit Hall 3. Regulatory News: Median Technologies FR0011049824, ALMDT, PEA/SME eligible...
► Artikel lesen
MEDIAN TECHNOLOGIES Aktie jetzt für 0€ handeln
06.09.Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of August 31st, 2024416Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares...
► Artikel lesen
04.09.Median Technologies to share positive pivotal data for eyonis LCS diagnostic software as medical device at the IASLC 2024 World Conference on Lung Cancer320(San Diego, CA, USA, from September 7-10, 2024) eyonis LCS is a proprietary Software as Medical Device (SaMD) powered by artificial intelligence (AI) machine learning (ML) for early detection...
► Artikel lesen
02.09.Median Technologies to host two webcasts on September 5, 2024281eyonis LCS: New Horizons in Fighting Lung Cancer" Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, "Median" or "The Company") will host two live webcasts on September...
► Artikel lesen
29.08.Median Technologies Announces Pivotal REALITY Study of Its eyonis LCS Lung Cancer Diagnostic Met All Primary and Secondary Endpoints247eyonis LCS met the primary endpoint for accuracy, achieving an Area Under the Curve (AUC)1 of 0.90, significantly above the 0.80 set for regulatory clearance. eyonis LCS met all 9 secondary...
► Artikel lesen
08.08.Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of July 31st, 2024245Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares...
► Artikel lesen
06.08.Median Technologies Partners with a Top 10 Oncology Pharma Company to Apply AI for Imaging Biomarker Discovery328The partnership's aim is to identify predictive imaging biomarkers of patient response to a specific drug-candidate, using Imaging Lab's unique AI capabilities. The company is a Top 10...
► Artikel lesen
18.07.Median Technologies Reports Record iCRO Backlog, eyonis LCS On-Track for Standalone Pivotal Study Readout in August436As of June 30, 2024, order backlog at €71.7 million, an all-time high for Median. First major iCRO deals in Japan and South Korea. China sales recovering and bookings growth accelerating....
► Artikel lesen
11.07.Median Technologies: Financial Communication Schedule for the Second Half of 2024394Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, "Median" or "the Company"), announces the publication date for its 2024 half year results and Q3, 2024 business activity:...
► Artikel lesen
05.07.Half year Median Technologies liquidity contract statement340Regulatory News: Under the liquidity contract entrusted by Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, "Median" or "the Company") to TP ICAP (Europe), the following resources were...
► Artikel lesen
03.07.Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of June 30th, 2024242Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares...
► Artikel lesen
07.06.Median Technologies: Disclosure of total number of voting rights and number of shares in the capital as of May 31st, 2024581Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares...
► Artikel lesen
03.06.Median Technologies Announces the Availability of the Preparatory Documents for the Shareholders' Ordinary and Extraordinary General Meeting on June 19, 2024244Regulatory News: The shareholders of Median Technologies FR0011049824, ALMDT, PEA/PME scheme eligible, "Median" or "The Company" are invited to participate in the Shareholders' Ordinary and Extraordinary...
► Artikel lesen
29.05.Median Technologies to Participate in the 2024 ASCO Annual Meeting, May 31 - June 4, 2024, McCormick Place, Chicago, IL, USA319Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA/PME scheme eligible, "Median" or "The Company") announced today that the Company will be participating in the 2024 American Society...
► Artikel lesen
21.05.Median Technologies, a World Leading Oncology Clinical Trial Imaging Services Provider, Becomes Preferred Vendor to Another Top 3 Pharmaceutical Company306Median Technologies has been selected as a preferred clinical trial imaging services provider for another leading global pharmaceutical company. Median Technologies is now preferred provider...
► Artikel lesen
Seite:  Weiter >>
41 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1